PD-1抑制剂逆转安罗替尼获得性耐药2例报道

Report of reversal of acquired resistance to anlotinib by PD-1 inhibitors in 2 cases

在本报道中,2例晚期口腔腺癌患者化疗后进展,改用安罗替尼治疗,肿瘤有缩小(疗效评价为SD)。病例1于安罗替尼治疗后2.8个月出现耐药,肿瘤进展,给予PD-1抑制剂(特瑞普利单抗)治疗1个周期,后再次使用安罗替尼治疗,肿瘤再次缩小(疗效评价为SD),目前仍然在维持治疗中。安罗替尼治疗的第1次无进展生存时间(PFS1)为2.8个月,第2次无进展生存时间(PFS2)为12.8+个月。病例2于安罗替尼治疗后15.5个月出现耐药,肿瘤进展,给予PD-1抑制剂(卡瑞利珠单抗)治疗4个周期,后再次使用安罗替尼治疗,肿瘤再次缩小(疗效评价为SD),目前仍然在维持治疗中。安罗替尼治疗的第1次无进展生存时间(PFS1)为15.5个月,第2次无进展生存时间(PFS2)为6.0+个月。这些病例显示,PD-1抑制剂可能逆转安罗替尼的获得性耐药,值得进一步研究。

In this report,two patients with advanced oral adenocarcinoma progressed after chemotherapy and were switched to anlotinib.The tumors shrank(the efficacy evaluation was SD).Case 1 developed drug resistance 2.8 months after treatment with Anlotinib and the tumor progressed.The patient was given PD-1 inhibitor(treplimumab)for 1 cycle,and then treated with anlotinib again.The tumor shrank again(the efficacy evaluation was SD).The patient was still under maintenance treatment.The first progression-free survival time(PFS1)of anlotinib treatment was 2.8 months,and the second progression-free survival time(PFS2)was 12.8+months.Case 2 developed drug resistance at 15.5 months after Anlotinib treatment,and the tumor progressed.The PD-1 inhibitor(carrelizumab)was given for 4 cycles,and then anlotinib was used again.The tumor shrank again(the efficacy evaluation was SD).The patient was still under maintenance treatment.The first progression-free survival time(PFS1)of anlotinib treatment was 15.5 months,and the second progression-free survival time(PFS2)was 6.0+months.These cases suggest that PD-1 inhibitors may reverse the acquired resistance of anlotinib,which is worthy of further study.